- Trial phase
- Phase 2
- Time to market
- At least 3-5 years away, assuming a successful Phase 2b/3 program is initiated and completed. The company has not announced a registrational trial start date and may need a partner to fund it.
- Why 4/10
- No hard, dated binary catalyst (PDUFA, pivotal readout, or AdComm) is scheduled in the next ~12 months. SGX945 is a mid-stage (Phase 2) asset with a completed 8-patient Phase 2a study. The next catalyst would likely be initiation of a larger Phase 2b/3 trial or a partnership announcement, neither of which has a confirmed date. The company is also evaluating strategic alternatives, which could produce news but is not a dated binary event.
Watch for any announcement from Soligenix regarding the next development steps for SGX945, including potential Phase 3 trial plans or a partnership/licensing deal. The company is actively evaluating strategic alternatives, so any M&A or partnership news could be a major catalyst. Also monitor for any new clinical trial initiations or regulatory milestone updates.
Price Chart
Executive Summary
SGX945 (dusquetide) is Soligenix's mid-stage investigational therapy for Behçet's Disease, a rare inflammatory disorder causing painful oral and genital ulcers. It uses a novel Innate Defense Regulator mechanism that modulates inflammation without suppressing the immune system. In a small 8-patient open-label Phase 2a study, 7 of 8 patients achieved complete resolution of oral ulcers with no treatment-related adverse events, comparing favorably to the approved competitor Otezla (apremilast). The drug has accumulated multiple regulatory designations (FDA Fast Track, US and EU Orphan Drug, UK PIM). However, Soligenix is a micro-cap company (market cap roughly $7.6M) with limited cash ($9.0M), a terminated Phase 3 program for another asset (HyBryte), and no confirmed timeline for the next pivotal trial. The company is evaluating strategic alternatives including partnerships and M&A.
How It Works
SGX945 (dusquetide) is a synthetic peptide that acts as an Innate Defense Regulator (IDR). Instead of suppressing the immune system like many anti-inflammatory drugs, it modulates the body's innate immune response to reduce harmful inflammation while preserving the ability to fight infections. It targets a specific cellular pathway (the P2X7 receptor) to dampen excessive inflammatory signaling without causing broad immunosuppression.
Trial Status
A Phase 2a proof-of-concept study (8 patients, open-label) was completed in mid-2025, with positive results published in Rheumatology (Oxford) in December 2025. A Phase 2 clinical trial (DUS-AUBD-01) was initiated in November 2024. The company has not announced whether a Phase 3 registrational trial has been designed or initiated.
The Two-Sided Case
Upcoming Catalysts
- Potential announcement of Phase 3 trial design or initiation
- Possible partnership, licensing, or M&A transaction as part of strategic alternatives review
- Any additional regulatory milestone or designation updates
- Potential Nasdaq compliance update given low stock price
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Soligenix, Inc. PRESS-RELEASE SNGX ·Originating report